CYTOTOXICITY ASSESSMENT OF ALPHA-MANGOSTEEN TOWARDS MITOCHONDRIAL TARGETED TRIPLE NEGATIVE BREAST CANCER (TNBC)

• Main Author: Fitriana, Devira
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/85414
• Institution: Institut Teknologi Bandung

Cancer is a disease characterized by the abnormal, rapid growth of cells, which can lead to metastasis. Cancer can affect various organs in the body, including the breast. Breast cancer can be classified into four molecular subtypes: luminal A, luminal B, HER2-enriched, and basal/TNBC (Triple Negative Breast Cancer). The TNBC subtype has the poorest prognosis due to the lack of expression of hormone receptors and HER2 (Human Epidermal Growth Factor Receptor 2). Current TNBC therapies have several drawbacks, such as resistance and potential toxicity to normal cells. Therefore, there is a need to develop alternative therapies that are more specific to TNBC. One strategy involves targeting cell mitochondria using mitotoxic compounds, as mitochondria are essential organelles involved in vital and lethal cell functions. Previously, a liposome-based ?-mangostin compound specifically targeting mitochondria, called lipoDQ ?-mangostin, was developed. In that research, the surface of liposomes containing ?-mangostin was modified with a mitochondriotropic agent, dequalinium chloride (DQA). This study aims to evaluate the in vitro cytotoxic activity of lipoDQ ?-mangostin against 4T1 cells, which are mammary carcinoma cells isolated from BALB/c mice as a model for TNBC. Characterization of the nanoparticles showed that lipoDQ ?-mangostin had a size of 150.13 ± 3.98 nm, a polydispersity index of < 0.3, a zeta potential of +11.31 ± 1.50 mV, and an active compound entrapment efficiency of > 80%. Cytotoxicity tests indicated that lipoDQ ?-mangostin exhibited higher toxicity compared to non-mitochondria-targeting ?-mangostin liposomes and ?-mangostin solution, with an IC50 of 57.92 ± 5.53 ?M. These results suggest that lipoDQ ?-mangostin has potential as an alternative therapy for TNBC.